$0.00
(Market cap
$6 Mln
Recently Viewed
Clear AllMarket cap
$6 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2323.8
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-134 Mln
ROE
-3.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-1.1
Debt to Equity
-1.4
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
58,028,300
CFO
$-659.21 Mln
EBITDA
$-744.82 Mln
Net Profit
$-790.92 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Tricida (TCDA)
| -90.8 | -29.5 | -90.6 | -99.8 | -91.6 | -- | -- |
|
BSE Sensex*
| -9.0 | 5.0 | -8.1 | -4.3 | 7.6 | 9.8 | 11.9 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|
|
Tricida (TCDA)
| -98.4 | 35.6 | -81.3 | 60.1 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Tricida (TCDA)
|
0.0 | 6.3 | 0.0 | -133.9 | -- | -- | -- | 2,323.8 |
| 76.4 | 10,475.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.8 | 18.4 | |
| 44.2 | 11,095.1 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.7 | 5.1 | |
| 91.2 | 11,613.4 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.6 | 7,577.6 | 1,396.6 | 316.9 | 59.8 | 153.6 | 25 | 155.2 | |
| 287.0 | 7,831.1 | 389.1 | 204.8 | 41.5 | 18.9 | 38.9 | 6.4 | |
| 518.7 | 11,844.1 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.7 | |
| 417.0 | 11,924.8 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.2 | 19.9 | |
| 102.6 | 7,822.0 | 0.0 | -425.4 | -- | -36.7 | -- | 6.3 | |
| 337.6 | 9,029.2 | 0.0 | -303.3 | -- | -45.8 | -- | 10.3 |
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with... chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California. On January 11, 2023, Tricida, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Read more
Founder, Pres, CEO & Exec. Director
Dr. Gerrit Klaerner Ph.D.
Founder, Pres, CEO & Exec. Director
Dr. Gerrit Klaerner Ph.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Tricida Inc (TCDA) is $0.01 (NASDAQ) as of 27-Mar-2023 09:30 EDT. Tricida Inc (TCDA) has given a return of -91.64% in the last 3 years.
Since, TTM earnings of Tricida Inc (TCDA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of Tricida Inc (TCDA) are Rs -- and Rs -- as of 05-May-2026.
Tricida Inc (TCDA) has a market capitalisation of $ 6 Mln as on 27-Mar-2023. As per SEBI classification, it is a company.
Before investing in Tricida Inc (TCDA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.